Tom’s Articles
-
Does Drug Discovery Anticipate Delivery?
10/28/2026
In this article, Chief Editor Tom von Gunden considers the relationship between drug discovery and drug delivery. His commentary includes reflections on conversations and encounters from the Discovery & Development US conference, where formulation and delivery topics were also in the air and on the agenda.
-
The Resurgence Of Fervor For Oral Delivery
10/7/2026
In this article, Chief Editor Tom von Gunden reports on the science and technology boosting the rise in attention to oral methods for advanced drug and biologics delivery. The insights he illuminates include innovative approaches to increasing permeability, solubility, and bioavailability, as well as expanding the types and sizes of therapeutic payloads formulated for oral administration.
-
Inquiries In Inhalation, Part 2: Having A Nose For Innovation
8/19/2026
In this follow-up article, Chief Editor Tom von Gunden extends his Part 1 discussion of therapeutic targets for inhaled drugs and biologics into specific aspects of delivery innovation. Among the key considerations are particle engineering, device usability, and the coordination across the ecosystem of inhalation delivery design, development, and distribution. The coverage of advances in device technologies includes inhalers, nebulizers, and nasal sprays.
-
Inquiries In Inhalation, Part 1: The Breadth Of Breath
8/12/2026
In this article, Chief Editor Tom von Gunden considers the expanding range of addressable targets for inhalation drug and biologics delivery. He reports on innovations in oral and nasal inhalation technology that enhance approaches to traditional respiratory indications, as well enable delivery of inhaled therapies to systemic targets beyond the nose and lungs.
-
Delivery Device Functional Scrutiny: Can You Pass (Without) The Test?
7/13/2026
In this article, Chief Editor Tom von Gunden considers the relationship between regulatory testing and the biopharma industry’s interest in leveraging drug delivery platform technologies to reduce regulatory burden in product development. Tom includes a conversation with guest columnist Doug Mead about waivers on testing in the context of FDA’s guidance on Essential Drug Delivery Outputs (EDDOs).
-
Need A Drug Delivery Conversation Starter? Try Target Product Profile
5/18/2026
In this article, Chief Editor Tom von Gunden explores the need for and existence of cross-functional communication during drug product development and delivery device selection. He consults industry veterans with experience in various formulation or delivery roles at GSK and Merck. They identify the Target Product Profile (TPP) as the core concept guiding collaboration.
-
Regulatory Attention To Human Factors: How Much Is There?
5/5/2026
In this article, Chief Editor Tom von Gunden considers trends in drug delivery likely to drive increased scrutiny around Human Factors {HF) in regulatory submissions and approvals. In an embedded video and transcript from Tom’s conversation with combination products consultant Doug Mead, the two discuss findings from GenAI queries that surfaced FDA precedents on HF-related matters including critical tasks, use errors, and risk mitigation.
-
Patient-Centric Drug Delivery: Do Possible And Preferable Always Align?
4/22/2026
In this article, Chief Editor Tom von Gunden discusses the alignment of drug delivery method with patient preference and need. He reflects on recent conversations in which he heard from experts in drug and delivery product development, as well as patients themselves, about patient-centric considerations such as safety, efficacy, usability, and convenience. The primary use case is the transition from clinically administered IV to subcutaneous injection, including self-administration.
-
Regulatory Precedents For Drug Delivery: Uncovering Clues To Successful Submissions
3/2/2026
In this article, Chief Editor Tom von Gunden considers the need for and benefit of conducting AI-based research into regulatory precedents for drug delivery submissions and approvals. He consults combination products consultant Doug Mead on best practices in bolstering regulatory intelligence and regulatory approval success by way of advanced search methods.
-
Combination: The Drug Delivery Word Of The Year For 2026
12/30/2025
In this article, Chief Editor Tom von Gunden explains why he sees 2026 as the year combination products and therapies become fully central to drug and biologics product development, delivery, and regulatory. He points to personalized medicine and patient self-administration as key factors shaping his view of the drug delivery landscape.